Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response.

Autor: Botson JK; Orthopedic Physicians Alaska 3801 Lake Otis Pkwy, Anchorage, AK, 99508, USA. jbotson@opaak.com., Baraf HSB; The Center for Rheumatology and Bone Research, 2730 University Blvd. West, Suite 310, Wheaton, MD, 20902, USA., Keenan RT; Duke University School of Medicine Duke Medicine Circle, 124 Davison Building, Durham, NC, 27710, USA., Albert J; Rheumatic Disease Center, 7080 N. Port Washington Road, Glendale, WI, 53217, USA., Masri KR; Rheumatology OnDemand, LLC 405 Welwyn Rd, Henrico, VA, 23229, USA., Peterson J; The Seattle Arthritis Clinic, Kirkland, WA, 98033, USA., Yung C; Private Practice, 2482 W Horizon Ridge Parkway, Suite 130, Henderson, NV, 89052, USA., Freyne B; Rheumatology Internal Medicine 39755, Murrieta Hot Springs Rd, Ste. F110, Murrieta, CA, 92563, USA., Amin M; Arizona Arthritis and Rheumatology Associates, 11943 East Beryl Ave, Scottsdale, AZ, 85259, USA., Abdellatif A; Baylor College of Medicine, 600 N Kobayashi Rd., Ste 312, Webster, TX, 77598, USA., Soloman N; Arizona Arthritis and Rheumatology Associates, 9097 W Roberta Ln, Phoenix, AZ, 85383, USA., Edwards NL; University of Florida, 1600 SW Archer Road, Room 4102, Gainesville, FL, 32610, USA., Strand V; Division of Immunology/Rheumatology, Stanford University, 306 Ramona Road, Portola Valley, CA, 94028, USA.
Jazyk: angličtina
Zdroj: Current rheumatology reports [Curr Rheumatol Rep] 2022 Jan; Vol. 24 (1), pp. 12-19. Date of Electronic Publication: 2022 Feb 15.
DOI: 10.1007/s11926-022-01055-9
Abstrakt: Purpose of Review: Gout is a systemic disease from which some patients develop numerous painful tophi that adversely affect quality of life and functionality. Some patients treated with oral urate-lowering therapy are unable to maintain serum urate levels below 6 mg/dL, and these patients, thus classified as having refractory or uncontrolled gout, often require therapy with pegloticase to reduce symptoms and tophaceous burden. The objective of this expert opinion review is to summarize the available evidence supporting the use of concomitant immunomodulators with pegloticase to prevent development of anti-drug antibodies (ADAs) when treating patients with uncontrolled gout.
Recent Findings: Emerging evidence suggests that adding an immunomodulator to pegloticase therapy can substantially increase response rates to double those observed in phase 3 randomized controlled trials. The combination of immunomodulation with pegloticase should be considered in routine clinical practice to improve durability of response, efficacy, and safety among patients with uncontrolled gout who otherwise have limited therapeutic options.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: